Prolactin serum concentrations during aripiprazole treatment in youth

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 4, 2013, Pages 282-289

  Safer, Daniel J ^a   Calarge, Chadi A ^b   Safer, Alan M ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PROLACTIN;

CALCULATION; COMPARATIVE STUDY; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HUMAN; PROLACTIN BLOOD LEVEL; REVIEW; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; QUINOLONES;

EID: 84878076871     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0062     Document Type: Review

References (90)

1. Aldrimer M, Ridefelt P, Rodoo R, Niklasson F, Gustafsson J, Hellberg D: Reference intervals on the Abbott Architect for serum thyroid hormones, lipids and prolactin in healthy children in a population-based study. Scand J Clin Lab Invest 72:326-332, 2012.
2. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL: Correlation of antipsychotic concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12:83-91, 2002.
3. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Doubleblind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:137-1346, 2002.
4. Becker AL, Epperson CN. Female puberty: Clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc Psychiatr Clin N Amer 15:207-220, 2006.
5. Beltran L, Fahie-Wilson MN, McKenna J, Kavanagh L, Smith TP: Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene gycol: evaluation and validation on common immunoassay platforms assay. Clin Chem 54:1673-1681, 2008.
6. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J: An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 12:683-689, 2007.
7. Biederman J,Mick E,Wozniak J, AleardiM, Spencer T, Faraone SV: An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15:311-317, 2005.
8. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19:373-382, 2009.
9. Chen CY, Lin TY, Wang CC, Shuai HA: Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: A case series. Psychiatry Clin Neurosci 65:95-97, 2011.
10. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL: Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol 68:66-71, 2008.
11. Colao A, Lombardi G, Annunziato L: Cabergoline. Expert Opin Pharmacother 1:555-574, 2000.
12. Cook JF, Hicks JM, Godwin ID, Bailey J, Soldin SJ: Pediatric reference ranges for prolactin. Clin Chem 38:959, 1992.
13. Cookson J, Hodgson R, Wlldgust HJ: Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 26 (5) Suppl:42-51, 2012.
14. Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, Boddi V, Bandini E, Balercia G, Forti G, Maggi M: Hypoprolactinemia: A new clinical syndrome in patients with sexual dysfunction. J Sex Med 6:1457-1466, 2009.
15. Douchi T, Nakae M, Yamamoto S, Iwamoto I, Oki T, Nagata Y: A woman with isolated prolactin deficiency. Acta Obstet Gynecol Scand 80:368-370, 2001.
16. Elmlinger MW, Kuhnel W, Ranke MB: Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med 40:1151-1160, 2002.
17. Ercan ES, Uysal T, Ercan E, Ardic A: Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. Pharmacopsychiatry 45:13-19, 2012.
18. Erickson CA, Stigler KA, Wink LK, Mullet JE, Kohn A, Posey DJ, McDougle CJ: A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology 216:85-90, 2011.
19. Falk RJ: Isolated prolactin deficiency: A case report. Fertil Steril 58:1060-1062, 1992.
20. Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott SA, Malikaajun S, Iwanoto T, McQuade RD, Boulton DW, Blumer J: An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19:431-439, 2009a.
21. Findling RL, McNamara NK, Youngstrom EA, Stansbrey RJ, Frazier TW, Lingler J, Otto BD, Demeter CA, Rowles BM, Calabrese JR: An open-label study of aripiprazole in children with a bipolar disorder. J Child Adolesc Psychopharmacol 21:345-351, 2011.
22. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanov S, Carson WH, Chang K: Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70:1441-1451, 2009b.
23. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008a.
24. Findling RL, Short E, Leskovec T, Townsend LD, Demeter CA, McNamara NK, Stansbrey RJ: Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18:347-354, 2008b.
25. Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C, Rowles BM, Demeter CA, Frazier TW, Calabrese JR: Double-blind, randomized, placebo-controlled longterm maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 73:57-63, 2012.
26. Foley KF, Kast RE: Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry 28:230-233, 2006.
27. Freeman ME, Kanyicska B, Lerant A, Nagy G: Prolactin: Structure function, and regulation of secretion. Physiol Rev 80:1522-1631, 2000.
28. Friesen H, Hwang P: Human prolactin Annu Rev Med 24:251-270, 1973.
29. Gassler N, Peuschel T, Pankau R: Pediatric reference values of estradiaol, testosterone, lutropin, follitropin and prolactin. Clin Lab 46:553-560, 2000.
30. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, Axelson DA, Bolhofner K, Robb A, Wolf DV, Riddle MA, Birmaher B, Nusrat N, Ryan NA, Vitiello B: A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 69:515-528, 2012.
31. Gentile S, Tofani S, Bellantuono C: Aripiprazole and pregnancy: A case report and literature review: J Clin Psychopharmacol 31:531-532, 2011.
32. Goldman-Rakic PS, Brown RM: Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Brain Res 256:339-349, 1982.
33. Gonzales GF, Valasquez G, Garcia-Hjarles M: Hypoprolactinemia as related to seminal quality and serum testosterone. Arch Androl 23:259-265, 1989.
34. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Fantz A, Halpern FS: Prolactin responses to neurolptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:108-116, 1978.
35. Haddad PM, Wieck A: Antipsychotic-induced hyperprolactinemia. Drugs 64:2291-2314, 2004.
36. Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W: The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients. BMC Psychiatry 22:95, 2008.
37. Hutchison P, Sill H: Lactation suppression with bromocriptine. N Z Med J 94:309-310, 1981.
38. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assuncao-Talbott S: A multicenter, randomized, double-blind, placrbo-controlled, 16-week study of aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70:1348-1357, 2009.
39. Kauppila A: Isolated prolactin deficiency in a woman with puerperal alactogenesis. J Clin Endocrinol Metab 64:309-312, 1987.
40. Kinon BJ, Gilmore JA, Liu H, Halbreich UM: Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28:69-82, 2003.
41. Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, Lee MS: Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci 64:38-43, 2010.
42. Lurie S, O'Quinn A: Neuroendocrine responses to methlphenidate and d-amphetamine: applications to attention-deficit disorder. J Neuropsychiatr 3:41-50, 1991.
43. Lutz UC, Hiemke C, Wiatr G, Farger G, Arand J, Wildgruber D: Aripiprazole in pregnancy and lactation: A case report. J Clin Psychopharmacol 30:204-205, 2010.
44. Lyon GJ, Samar S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey BJ: Aripiprazole in children and adolescents with Tourette's Disorder: An open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19:623-633, 2009.
45. Mallikaarjun S, Salazar DE, Bramer SL: Pharmcokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal volunteers. J Clin Pharmacol 44:179-187, 2004.
46. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, CarsonW, Aman MG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
47. Marcus R, Owen R , Manos G , Mankoski R, Kamen L, McQuade RD, CarsonWH, Findling RL: Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry 72:1270-1276, 2011.
48. Melmed S, Kleinberg, Ho K: Pituitary physiology and diagnostic evaluation. In: Melmed S, Polonsky KS, Larsen PR, Kronenbrg HM, eds. Williams Textbook of Endocrinology, 12th ed. Philadelphia: Elsevier; 2011, pp. 175-228.
49. Meltzer HY, Sachar EJ, Frantz AG: Serum prolactin levels in unmedicated schizophrenic patients. Arch Gen Psychiatry 31:564-569, 1974.
50. Mendhekar DN, Sharma JB, Srilakshmi P: Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother 40:575, 2006a
51. Mendhekar DN, Sunder KR, Andrade C: Aripiprazole use in pregnant schizoaffective woman. Bipolar Disord 8:299-300, 2006.
52. Mervak B, Collins J, Valenstein M: Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health 11:249-250, 2008.
53. Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germano E, Siracusano R, Diaz FJ, deLeon J: Short-and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry 33:1496-1501, 2009.
54. Mood's Median Test. In: Siegel S, Castellan NJ, eds. Non-parametric Statistics for the Behavioral Sciences. 2nd ed, pp. 124-128. New York: McGraw-Hill; 1988.
55. Musil R, Riedel M, Spellmann I, Opgen-Rhein M, Schwarz MJ: Changes in prolactin levels as predictor of response to treatment with aripiprazole. Brain Behav Immun 23 (Suppl 1):S16, 2009.
56. Nguyen T, Teoh S, Hackett LP, Ilett K: Placental transfer of aripiprazole. Aust N Z J Psychiatry 45:500-501, 2011.
57. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533-1540, 2009.
58. Paing WW, Weller RZ, Sheikh R, Weller EB: Minimizing the impact of elevated prolactin in children and adolescents. Curr Psychiatr 10:47-57, 2011.
59. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadeleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU: Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563-573, 2009.
60. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690, 2003.
61. Rinne JO, Lonnberg P, Marjamaki P: Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res 508:349-352, 1990.
62. Rothmond DA, Weickert, CS, Webster MJ: Developomental changes in human dopamine neurotransmission: cortical receptors and terminators. BMC Neurosci 13:18, 2012.
63. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 20:536-546, 2006.
64. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperporlactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Paychopharmacol 14:350-358, 2004.
65. Sallee FR, Gilbert DL, Vinks AA, Miceli JJ, Robarge L, Wilner K: Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry 42:902-907, 2003.
66. Sarin A, Nagpal SA, Bohra NK, Jiloha RC, Rao GP, Sharma SK, Vaishnav M, Vaya L, Karan RS, Patel NK, Patel R: Open labeled, randomized, switch-over study of two fixed doses (10/15 mg) of aripiprazole in the treatment of Indian patients with schizophrenia. Indian J Psychiatry 46:64-71, 2004.
67. Schuster D, Gaines-Das RE, Jeffcoate SL: International standards for human prolactin: calibration by international collaborative study. J Endocrinol 121:157-166, 1989.
68. Seeman P, Bzowei NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, Bird ED, Riederer P, Jellinger K, Watanabe S: Human brain dopamine receptors in children and aging adults. Synapse 1:399-404, 1987.
69. Siemens Medical Solutions. Prolaktin, 2012. Available at www.medical.siemens.com/siemens/en-GLOBAL/gg-diag-FBAs/files/referenzwerte-pdf/ IMMULITE-Systeme/prolaktin.pdf. Last accessed October 2012.
70. Shim JC, Shin JK, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR: Adjunctive treatment with a dopamine partialagonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry 164:1404-1410, 2007.
71. Soldin SJ. Morales A, Albalos F, Lenherr S, Rifai N: Pediatric reference ranges on the Abbott IMx for FSH, LH, Prolactin, TSH, T4, T3, free T3, IgE, and Ferritin. Clin Biochem 28:603-606, 1995.
72. Spitz M, Landau H, Almallach U, Rosen E, Braubar N, Russell A: Diminished prolactin reserve: A case report. J Clin Endocrinol Metab 45:412-418, 1977.
73. Staller J: The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 16:317-326, 2006.
74. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ: Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's Disorder: A 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19:265-274, 2009.
75. Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ: Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology 223:237-245, 2012.
76. Suescun MO, Scorticati C, Chiauzzi VA, Chemes HE, Rivarola MA, Calandra RS: Induced hypoproactinemia and testicular steroidogenesis in man. J Androl 6:10-14, 1985.
77. Tan DY, Peng XP: Progress in prolactin reseptor research. Sheng Li Ke Xue Jin Zhan 43:17-23, 2012.
78. Taylor AM: Pediatric Focused Safety Review. Abilify (aripiprazole), 2011. Available at www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/pediatricadvisorycommittee/UCM272 850.pdf Accessed April, 2012.
79. Turkington RW: Phenothiazine stimulation test for prolactin reserve: the syndrome of isolated prolactin deficiency. J Clin Endocrinol Metab 34:247-249, 1972.
80. Ufearo CS, Orisakwe OE: Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metaclopramide and exogenous human prolactin. Clin Pharmacol Ther 58:354-359, 1995.
81. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania. Br J Psychiatry 187:235-242, 2005.
82. Watanabe N. Kasahara M, Sugibayashi R, Nakamura T, Nakajima K, Watanabe O, Murashima A: Perinatal use of aripiprazole: A case report. J Clin Psychopharmacol 31:377-379, 2011.
83. Weickert CS, Webster MJ, Gondipalli P. Rothmond D, Fatula RJ, Herman MM, Kleinman JE, Akil M: Postnatal alterations in dopaminergic markers in the human prefrontal cortex. Neuroscience 144:1109-1119, 2007.
84. Widschwendter CG, Hofer A: Aripoprazole use in early pregnancy: A case report. Pharmacopsychiatry 45:200-300, 2012.
85. Wiedemann G, Jonetz-Mentzel L: Establishment of reference ranges for prolactin in neonates, infants, children and adolescents. Eur J Clin Chem Clin Biochem 31:447-451, 1993.
86. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.
87. Yasui-Furukori N, Furukori H, Sugawara , Fujii A, Kaneko S: Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 30:596-599, 2010.
88. Zargar AH, Masoodi SR, Laway BA, Shah NA, Salahudin M: Familial puerperal alactogenesis: Possibility of a genetically transmitted isolated prolactin deficiency. Br J Obstet Gynaecol 104:629-631, 1997.
89. Zhang J: FDA clinical review. Abilify sNDA 21-436/027, 2009. Available at www.fda.gov/downloads/Drugs/DevelopmentApproval Process/DevelopmentResources/ UCM241795.pdf
90. Zhang J: FDA clinical review. Aripiprazole NDA 21436-021, 2008. Available at www.fda.gov/downloads/Drugs/DevelopmentApproval Process/ DevelopmentResources/UCM071737.pdf